Abstract
It has been known for more than 30 years that individuals vary in their ability to metabolize therapeutically useful molecules. This variation is due in large part to genetic differences among individuals. Humans are exposed to thousands of natural and synthetic compounds, in addition to drugs, that must be metabolized to become carcinogenic. Genetic variation in the encoded enzymes involved in this metabolism is thought to be the basis for some of the differences in cancer susceptibility among individuals. The study of how genetic variation affects the metabolism of drugs and other compounds is called pharmacogenetics.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Smith G, Stanley LA, Sim E, et al.: Metabolic polymorphisms and cancer susceptibility. Cancer Sury 1995, 25: 27–65.
Nelson DR, Koymans L, Kamataki T, et al: P450 super-family: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996, 6: 1–42.
Gonzalez FJ: The role of carcinogen-metabolizing enzyme polymorphisms in cancer susceptibility. Reprod Toxicol 1997, 11: 397–412.
Goto I, Yoneda S, Yamamoto M, Kawajiri K: Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res 1996, 56: 3725–3730.
Crofts F, Taioli E, Trachman J, et al. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994, 15: 2961–2963.
Horio Y, Takahashi T, Kuroishi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993, 53: 1–4.
Mitsudomi T, Oyama T, Kusano T, et al.: Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 1993, 85: 2018–2023.
Kawajiri K, Eguchi H, Nakachi K, et al.: Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 1996, 56: 72–76.
Storey A, Thomas M, Kalita A, et al.: Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998, 393: 229–234.
Rebbeck TR: Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prey 1997, 6: 733–743.
McWilliams JE, Sanderson BJ, Harris EL, et al.: Glutathione S-transferase M1 (GSTM1) deficiency and lung cancer risk. Cancer Epidemiol Biomarkers Prey 1995, 4: 589–594.
Deakin M, Elder J, Hendrickse C, et al.: Glutathione Stransferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis 1996, 17: 881–884.
Elexpuru-Camiruaga J, Buxton N, Kandula V, et al.: Susceptibility to astrocytoma and meningioma: influence of allelism at glutathione S-transferase (GSTT1 and GSTM1) and cytochrome P-450 (CYP2D6) loci. Cancer Res 1995, 55: 4237–4239.
Dekant W, Vamvaka S, Anders MW: Formation and fate of nephrotoxic and cytotoxic glutathione S-conjugates: cysteine conjugate beta-lyase pathway. Adv Pharmacol 1994, 27: 114–162.
Meyer UA, Zanger UM: Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997, 37:269–296.
Mahgoub A, Idle JR, Dring LG, et al.: Polymorphic hydroxylation of Debrisoquine in man. Lancet 1977, 2: 584–586.
Gonzalez FJ, Skoda RC, Kimura S, et al.: Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988, 331: 442–446.
Caporaso N, DeBaun MR, Rothman N: Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association. Pharmacogenetics 1995, 5: S129–134.
Lang NP, Butler MA, Massengill J, et al.: Rapid metabol- ic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne hetero- cyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prey 1994, 3: 675–682.
Morrison GB, Bastian A, Dela Rosa T, et al.: Dihydropyrimidine dehydrogenase deficiency: a pharmacogenetic defect causing severe adverse reactions to 5-fluorouracil-based chemotherapy. Oncol Nurs Forum 1997, 24: 83–88.
Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993, 53: 5433–5438.
McMurrough J, McLeod HL: Analysis of the dihydropyrimidine dehydrogenase polymorphism in a British population. Br J Clin Pharmaco1, 1996, 41: 425–427.
Ridge SA, Brown O, McMurrough J, et al.: Mutations at codon 974 of the DPYD gene are a rare event. Br J Cancer 1997, 75: 178–179.
Van Kuilenburg AB, Vreken P, Beex LV, et al.: Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur J Cancer 1997, 33: 2258–2264.
Wei X, McLeod HL, McMurrough, J, et al.: Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996, 98, 610–615.
Morgan AS, Sanderson PE, Borch RF, et al.: Tumor efficacy and bone marrow sparing properties of Ter 286, a cytotoxin activated by glutathione S-transferase. Cancer Res 1998, 58: 2568–2575.
Nebert DW, McKinnon RA, Puga A: Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol 1996, 15: 273–280.
Kadlubar FF, Butler MA, Kaderlik KR, et al.: Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ Health Perspect 1992, 98: 69–74.
Tew KD: Glutathione associated enzyme in anticancer drug resistance. Perspectives in cancer research. Cancer Res 1994, 54: 4313–4320.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Current Medicine, Inc.
About this chapter
Cite this chapter
Kruger, W.D., Tew, K.D. (2000). Pharmacogenetics and Cancer. In: Kruh, G.D., Tew, K.D. (eds) Basic Science of Cancer. Current Medicine Group. https://doi.org/10.1007/978-1-4684-8437-3_13
Download citation
DOI: https://doi.org/10.1007/978-1-4684-8437-3_13
Publisher Name: Current Medicine Group
Print ISBN: 978-1-4684-8439-7
Online ISBN: 978-1-4684-8437-3
eBook Packages: Springer Book Archive